STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping industry job market, and some curious explanations for clinical failures.
283: A CRISPR milestone, algorithms amok, & biotech mixology
Our colleague Casey Ross joins us to tell the bombshell story of how the nation's largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
From our reporting partners at Tradeoffs: Congress banned most surprise medical bills back in 2020, with one major exception: ambulance rides. Most people agree that patients should be shielded from these unexpected charges. But who should pick up the tab instead?
This week, as state and federal policymakers grapple with that question, we delve into why finding a fair solution is harder than you’d think.
You can also check out our STAT story for more information.
Note: This episode has been re-uploaded after technical difficulties.
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.
To keep up between podcast episodes, here’s where you can subscribe to our biotech newsletter, The Readout.
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.
For more on what we cover, here's where you can read Frank's work; here's more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here's where you can subscribe to our biotech newsletter, The Readout.
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week's big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round.
For more on what we cover, here's STAT's coverage of the European Society for Medical Oncology meeting; here's more on Roivant Sciences; here's the latest on biotech venture capital; here's more on the latest Alzheimer's data; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.
Amazing content — the podcast hosts really understand the biopharma field (both the science and history) and their jokes are also quite funny.
Good podcast but that theme song
Great content, smart hosts but that theme song/intro is jarring and amateurish.
Absolutely thrilled about this phenomenal podcast centered on pharma and biotech news! Weekly episodes are fantastic, though I’d be over the moon if they could dive even deeper and extend the show’s length. Keep up the awesome work! Welcome back, Allison (DeAngelis)!